 [1m([0morchestrator-angioedema-ALENDRONATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ALENDRONATE increase or decrease the risk of angioedema?[0m
 [1m([0morchestrator-angioedema-ALENDRONATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-ALENDRONATE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-angioedema-ALENDRONATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ALENDRONATE increase the risk of angioedema?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-angioedema-ALENDRONATE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ALENDRONATE increase the risk of angioedema?[0m
 [1m([0morchestrator-angioedema-ALENDRONATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-ALENDRONATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-angioedema-ALENDRONATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ALENDRONATE increase the risk of angioedema?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ALENDRONATE increase the risk of angioedema?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ALENDRONATE"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: ALENDRONATE: adverse_reactions_table: [0m[1;31m0[0m[1;31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Dyspepsia<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.7[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.2[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Acid regurgitation<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.9[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.4[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> [0m
[31mNausea<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.9[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.4[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Abdominal distention<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.4[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Constipation<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.8[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.6[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> [0m
[31mFlatulence<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.4[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.6[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Gastritis<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.2[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1[0m[31m. ALENDRONATE: adverse_reactions_table: [0m[1;31m1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Gastric ulcer<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m
[31mcolspan[0m[31m=[0m[31m"3"[0m[31m>Musculoskeletal<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Musculoskeletal [0m[1;31m([0m[31mbone, muscle, joint[0m[1;31m)[0m[31m pain<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.9[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m3.2[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Muscle cramp<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.2[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1[0m[31m. ALENDRONATE: [0m
[31madverse_reactions_table: [0m[1;31m1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mtbody[0m[31m><[0m[31m/[0m[31mtable[0m[31m>         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: warnings_and_cautions: [0m[1;31m5[0m[31m WARNINGS AND PRECAUTIONS Upper Gastrointestinal Adverse Reactions can occur. Instruct patients to follow dosing instructions. Discontinue if new or [0m
[31mworsening symptoms occur. [0m[1;31m([0m[31m [0m[1;31m5.1[0m[31m [0m[1;31m)[0m[31m Hypocalcemia can worsen and must be corrected prior to use. [0m[1;31m([0m[31m [0m[1;31m5.2[0m[31m [0m[1;31m)[0m[31m Severe Bone, Joint, Muscle Pain may occur. Discontinue use if severe symptoms develop. [0m[1;31m([0m[31m [0m[1;31m5.3[0m[31m [0m[1;31m)[0m[31m [0m
[31mOsteonecrosis of the Jaw has been reported. [0m[1;31m([0m[31m [0m[1;31m5.4[0m[31m [0m[1;31m)[0m[31m Atypical Femur Fractures have been reported. Patients with new thigh or groin pain should be evaluated to rule out a femoral fracture. [0m[1;31m([0m[31m [0m[1;31m5.5[0m[31m [0m[1;31m)[0m[31m [0m
[31mSodium Content: Each tablet contains [0m[1;31m603[0m[31m mg sodium, equivalent to [0m[1;31m1532[0m[31m mg NaCl. Use caution in patients on sodium restriction. [0m[1;31m([0m[31m [0m[1;31m5.7[0m[31m [0m[1;31m)[0m[31m [0m[1;31m5[0m[31m. ALENDRONATE: warnings_and_cautions: [0m[1;31m1[0m[31m Upper Gastrointestinal [0m
[31mAdverse Reactions BINOSTO, like other bisphosphonates administered orally, may cause local irritation of the upper gastrointestinal mucosa. Because of these possible irritant effects and a potential [0m
[31mfor worsening of the underlying disease, caution should be used when BINOSTO is given to patients with active upper gastrointestinal problems [0m[1;31m([0m[31msuch as known Barrett's esophagus, dysphagia, other [0m
[31mesophageal diseases, gastritis, duodenitis, or ulcers[0m[1;31m)[0m[31m. Esophageal adverse experiences, such as esophagitis, esophageal ulcers and esophageal erosions, occasionally with bleeding and rarely followed [0m
[31mby esophageal stricture or perforation, have been reported in patients receiving treatment with oral bisphosphonates including alendronate sodium. In some cases these have been severe and required [0m
[31mhospitalization. ALENDRONATE: warnings_and_cautions: Physicians should therefore be alert to any signs or symptoms signaling a possible esophageal reaction and patients should be instructed to [0m
[31mdiscontinue BINOSTO and seek medical attention if they develop dysphagia, odynophagia, retrosternal pain or new or worsening heartburn. The risk of severe esophageal adverse experiences appears to be [0m
[31mgreater in patients who lie down after taking oral bisphosphonates including alendronate sodium, and/or who continue to take oral bisphosphonates including alendronate sodium after developing symptoms[0m
[31msuggestive of esophageal irritation. Therefore, it is very important that the full dosing instructions are provided to, and understood by, the patient [0m[31m . In patients who cannot comply with dosing [0m
[31minstructions due to mental disability, therapy with BINOSTO should be used under appropriate supervision.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: adverse_reactions: [0m[1;31m6[0m[31m ADVERSE REACTIONS The most common adverse reactions [0m[1;31m([0m[31mincidence greater than or equal to [0m[1;31m3[0m[31m%[0m[1;31m)[0m[31m are abdominal pain, acid regurgitation, constipation, diarrhea, [0m
[31mdyspepsia, musculoskeletal pain, and nausea. [0m[1;31m([0m[31m [0m[1;31m6.1[0m[31m [0m[1;31m)[0m[31m To report SUSPECTED ADVERSE REACTIONS, contact Radius Health, Inc. at [0m[1;31m1[0m[31m-[0m[1;31m855[0m[31m-[0m[1;31m672[0m[31m-[0m[1;31m3487[0m[31m or FDA at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-FDA-[0m[1;31m1088[0m[31m or www.fda.gov/medwatch [0m[1;31m6.1[0m[31m Clinical [0m
[31mTrials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the [0m
[31mclinical trials of another drug and may not reflect the rates observed in clinical practice. ALENDRONATE: adverse_reactions: The safety of BINOSTO [0m[1;31m([0m[31malendronate sodium[0m[1;31m)[0m[31m effervescent tablet [0m[1;31m70[0m[31m mg is [0m
[31mbased on clinical trial data of alendronate sodium [0m[1;31m10[0m[31m mg daily and alendronate sodium [0m[1;31m70[0m[31m mg weekly. Treatment of Osteoporosis in Postmenopausal Women Daily Dosing The safety of alendronate sodium [0m[1;31m10[0m[31m [0m
[31mmg daily in the treatment of postmenopausal osteoporosis was assessed in four clinical trials that enrolled [0m[1;31m7453[0m[31m women aged [0m[1;31m44[0m[31m-[0m[1;31m84[0m[31m years. Study [0m[1;31m1[0m[31m and Study [0m[1;31m2[0m[31m were identically designed, three-year, [0m
[31mplacebo-controlled, double-blind, multicenter studies [0m[1;31m([0m[31mUnited States and Multinational [0m[31mn[0m[31m=[0m[1;31m994[0m[1;31m)[0m[31m; Study [0m[1;31m3[0m[31m was the three year vertebral fracture cohort of the Fracture Intervention Trial [0m[1;31m[[0m[31mFIT[0m[1;31m][0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m2027[0m[1;31m)[0m[31m [0m
[31mand Study [0m[1;31m4[0m[31m was the four-year clinical fracture cohort of FIT [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m4432[0m[1;31m)[0m[31m. ALENDRONATE: adverse_reactions: Overall, [0m[1;31m3620[0m[31m patients were exposed to placebo and [0m[1;31m3432[0m[31m patients exposed to alendronate. [0m
[31mPatients with pre-existing gastrointestinal disease and concomitant use of non-steroidal anti-inflammatory drugs were included in these clinical trials. In Study [0m[1;31m1[0m[31m and Study [0m[1;31m2[0m[31m all women received [0m[1;31m500[0m[31m [0m
[31mmg elemental calcium as carbonate. In Study [0m[1;31m3[0m[31m and Study [0m[1;31m4[0m[31m all women with dietary calcium intake less than [0m[1;31m1000[0m[31m mg per day received [0m[1;31m500[0m[31m mg calcium and [0m[1;31m250[0m[31m IU Vitamin D per day. Among patients treated [0m
[31mwith alendronate [0m[1;31m10[0m[31m mg or placebo in Study [0m[1;31m1[0m[31m and Study [0m[1;31m2[0m[31m, and all patients in Study [0m[1;31m3[0m[31m and Study [0m[1;31m4[0m[31m, the incidence of all-cause mortality was [0m[1;31m1.8[0m[31m% in the placebo group and [0m[1;31m1.8[0m[31m% in the alendronate group.[0m
[31mThe incidence of serious adverse events was [0m[1;31m30.7[0m[31m% in the placebo group and [0m[1;31m30.9[0m[31m% in the alendronate group.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: indications_and_usage: [0m[1;31m1[0m[31m INDICATIONS AND USAGE BINOSTO is a bisphosphonate indicated for: Treatment of osteoporosis in postmenopausal women [0m[1;31m([0m[31m [0m[1;31m1.1[0m[31m [0m[1;31m)[0m[31m Treatment to increase bone [0m
[31mmass in men with osteoporosis [0m[1;31m([0m[31m [0m[1;31m1.2[0m[31m [0m[1;31m)[0m[31m Limitation of use: Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after [0m[1;31m3[0m[31m to [0m[1;31m5[0m[31m years of use[0m
[1;31m([0m[31m [0m[1;31m1.3[0m[31m [0m[1;31m)[0m[31m [0m[1;31m1.1[0m[31m Treatment of Osteoporosis in Postmenopausal Women BINOSTO effervescent tablet [0m[1;31m70[0m[31m mg is indicated for the treatment of osteoporosis in postmenopausal women. For the treatment of [0m
[31mosteoporosis, alendronate sodium increases bone mass and reduces the incidence of fractures, including those of the hip and spine [0m[1;31m([0m[31mvertebral compression fractures[0m[1;31m)[0m[31m. [0m[1;31m[[0m[31mSee Clinical Studies [0m[1;31m([0m[1;31m14.1[0m[1;31m)[0m[31m .[0m[1;31m][0m[31m [0m[1;31m1[0m[31m. [0m
[31mALENDRONATE: indications_and_usage: [0m[1;31m2[0m[31m Treatment to Increase Bone Mass in Men With Osteoporosis BINOSTO is indicated for treatment to increase bone mass in men with osteoporosis [0m[31m . [0m[1;31m1.3[0m[31m Important [0m
[31mLimitations of Use The optimal duration of use has not been determined. The safety and effectiveness of BINOSTO for the treatment of osteoporosis are based on clinical data of four years duration. All[0m
[31mpatients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. Patients at low-risk for fracture should be considered for drug discontinuation after [0m[1;31m3[0m[31m [0m
[31mto [0m[1;31m5[0m[31m years of use. Patients who discontinue therapy should have their risk for fracture re-evaluated periodically.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: mechanism_of_action: [0m[1;31m12.1[0m[31m Mechanism of Action Animal studies have indicated the following mode of action. At the cellular level, alendronate shows preferential localization to [0m
[31msites of bone resorption, specifically under osteoclasts. The osteoclasts adhere normally to the bone surface but lack the ruffled border that is indicative of active resorption. Alendronate does not [0m
[31minterfere with osteoclast recruitment or attachment, but it does inhibit osteoclast activity. Studies in mice on the localization of radioactive [0m[1;31m[[0m[31m [0m[1;31m3[0m[31m H[0m[1;31m][0m[31malendronate in bone showed about [0m[1;31m10[0m[31m-fold higher [0m
[31muptake on osteoclast surfaces than on osteoblast surfaces. Bones examined [0m[1;31m6[0m[31m and [0m[1;31m49[0m[31m days after [0m[1;31m[[0m[31m [0m[1;31m3[0m[31m H[0m[1;31m][0m[31malendronate administration in rats and mice, respectively, showed that normal bone was formed on top[0m
[31mof the alendronate, which was incorporated inside the matrix. While incorporated in bone matrix, alendronate is not pharmacologically active. ALENDRONATE: mechanism_of_action: Thus, alendronate must [0m
[31mbe continuously administered to suppress osteoclasts on newly formed resorption surfaces. Histomorphometry in baboons and rats showed that alendronate treatment reduces bone turnover [0m[1;31m([0m[31mi.e., the number[0m
[31mof sites at which bone is remodeled[0m[1;31m)[0m[31m. In addition, bone formation exceeds bone resorption at these remodeling sites, leading to progressive gains in bone mass.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: openfda: spl_set_id         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: clinical_pharmacology: [0m[1;31m12[0m[31m CLINICAL PHARMACOLOGY [0m[1;31m12.1[0m[31m Mechanism of Action Animal studies have indicated the following mode of action. At the cellular level, alendronate shows [0m
[31mpreferential localization to sites of bone resorption, specifically under osteoclasts. The osteoclasts adhere normally to the bone surface but lack the ruffled border that is indicative of active [0m
[31mresorption. Alendronate does not interfere with osteoclast recruitment or attachment, but it does inhibit osteoclast activity. Studies in mice on the localization of radioactive [0m[1;31m[[0m[31m [0m[1;31m3[0m[31m H[0m[1;31m][0m[31malendronate in [0m
[31mbone showed about [0m[1;31m10[0m[31m-fold higher uptake on osteoclast surfaces than on osteoblast surfaces. Bones examined [0m[1;31m6[0m[31m and [0m[1;31m49[0m[31m days after [0m[1;31m[[0m[31m [0m[1;31m3[0m[31m H[0m[1;31m][0m[31malendronate administration in rats and mice, respectively, showed [0m
[31mthat normal bone was formed on top of the alendronate, which was incorporated inside the matrix. ALENDRONATE: clinical_pharmacology: While incorporated in bone matrix, alendronate is not [0m
[31mpharmacologically active. Thus, alendronate must be continuously administered to suppress osteoclasts on newly formed resorption surfaces. Histomorphometry in baboons and rats showed that alendronate [0m
[31mtreatment reduces bone turnover [0m[1;31m([0m[31mi.e., the number of sites at which bone is remodeled[0m[1;31m)[0m[31m. In addition, bone formation exceeds bone resorption at these remodeling sites, leading to progressive gains in [0m
[31mbone mass. [0m[1;31m12.2[0m[31m Pharmacodynamics Alendronate is a bisphosphonate that binds to bone hydroxyapatite and specifically inhibits the activity of osteoclasts, the bone-resorbing cells. Alendronate reduces [0m
[31mbone resorption with no direct effect on bone formation, although the latter process is ultimately reduced because bone resorption and formation are coupled during bone turnover. ALENDRONATE: [0m
[31mclinical_pharmacology: Osteoporosis in Postmenopausal Women Osteoporosis is characterized by low bone mass that leads to an increased risk of fracture. The diagnosis can be confirmed by the finding of[0m
[31mlow bone mass, evidence of fracture on x-ray, a history of osteoporotic fracture, or height loss or kyphosis, indicative of vertebral [0m[1;31m([0m[31mspinal[0m[1;31m)[0m[31m fracture. Osteoporosis occurs in both males and females [0m
[31mbut is most common among women following the menopause, when bone turnover increases and the rate of bone resorption exceeds that of bone formation. These changes result in progressive bone loss and [0m
[31mlead to osteoporosis in a significant proportion of women over age [0m[1;31m50[0m[31m. Fractures, usually of the spine, hip, and wrist, are the common consequences. From age [0m[1;31m50[0m[31m to age [0m[1;31m90[0m[31m, the risk of hip fracture in [0m
[31mwhite women increases [0m[1;31m50[0m[31m-fold and the risk of vertebral fracture [0m[1;31m15[0m[31m- to [0m[1;31m30[0m[31m-fold.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: contraindications: [0m[1;31m4[0m[31m CONTRAINDICATIONS BINOSTO is contraindicated in patients with the following conditions: Abnormalities of the esophagus which delay esophageal emptying such [0m
[31mas stricture or achalasia [0m[31m Inability to stand or sit upright for at least [0m[1;31m30[0m[31m minutes [0m[31m Do not administer BINOSTO to patients at increased risk of aspiration Hypocalcemia [0m[31m Hypersensitivity to any [0m
[31mcomponent of this product. Hypersensitivity reactions including urticaria and angioedema have been reported [0m[31m . Abnormalities of the esophagus which delay emptying such as stricture or achalasia [0m[1;31m([0m[31m [0m[1;31m4[0m[31m , [0m
[1;31m5[0m[31m. ALENDRONATE: contraindications: [0m[1;31m1[0m[31m [0m[1;31m)[0m[31m Inability to stand/sit upright for at least [0m[1;31m30[0m[31m minutes [0m[1;31m([0m[31m [0m[1;31m4[0m[31m , [0m[1;31m5.1[0m[31m [0m[1;31m)[0m[31m Increased risk of aspiration. [0m[1;31m([0m[31m [0m[1;31m4[0m[31m [0m[1;31m)[0m[31m Hypocalcemia [0m[1;31m([0m[31m [0m[1;31m4[0m[31m , [0m[1;31m5.2[0m[31m [0m[1;31m)[0m[31m Hypersensitivity to any component[0m
[31mof this product [0m[1;31m([0m[31m [0m[1;31m4[0m[31m , [0m[1;31m6[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: adverse_reactions_table: >[0m[1;31m10[0m[31m mg % [0m[1;31m([0m[31mN = [0m[1;31m146[0m[1;31m)[0m[31m<[0m[31m/[0m[31mth[0m[31m><th>Placebo % [0m[1;31m([0m[31mN = [0m[1;31m95[0m[1;31m)[0m[31m<[0m[31m/[0m[31mth[0m[31m><th>[0m[1;31m70[0m[31m mg % [0m[1;31m([0m[31mN = [0m[1;31m109[0m[1;31m)[0m[31m<[0m[31m/[0m[31mth[0m[31m><th>Placebo % [0m[1;31m([0m[31mN = [0m[1;31m58[0m[1;31m)[0m[31m<[0m[31m/[0m[31mth[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mthead[0m[31m><tbody><tr><td [0m
[31mcolspan[0m[31m=[0m[31m"5"[0m[31m>Gastrointestinal<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Acid regurgitation<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m4.1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m3.2[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> [0m
[31mFlatulence<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m4.1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Gastroesophageal reflux disease<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.7[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m3.2[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2[0m[31m. ALENDRONATE: adverse_reactions_table: [0m
[1;31m8[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Dyspepsia<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m3.4[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.8[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.7[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Diarrhea<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.4[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.8[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Abdominal [0m
[31mpain<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.9[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m3.4[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Nausea<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0[0m[31m. ALENDRONATE: adverse_reactions_table: [0m[1;31m0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mtbody[0m[31m><[0m[31m/[0m[31mtable[0m[1;31m>[0m[31m         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: adverse_reactions: [0m[1;31m1[0m[31m Musculoskeletal Musculoskeletal [0m[1;31m([0m[31mbone, muscle, joint[0m[1;31m)[0m[31m pain [0m[1;31m2.9[0m[31m [0m[1;31m3.2[0m[31m Muscle cramp [0m[1;31m0.2[0m[31m [0m[1;31m1.1[0m[31m Osteoporosis in Men In two placebo-controlled, double-blind, [0m
[31mmulticenter studies in men [0m[1;31m([0m[31ma two-year study of alendronate sodium [0m[1;31m10[0m[31m mg/day and a one-year study of once weekly alendronate sodium [0m[1;31m70[0m[31m mg[0m[1;31m)[0m[31m the rates of discontinuation of therapy due to any clinical [0m
[31madverse event were [0m[1;31m2.7[0m[31m% for alendronate [0m[1;31m10[0m[31m mg/day vs. [0m[1;31m10.5[0m[31m% for placebo, and [0m[1;31m6.4[0m[31m% for once weekly alendronate [0m[1;31m70[0m[31m mg vs. [0m[1;31m8.6[0m[31m% for placebo. The adverse reactions considered by the investigators as [0m
[31mpossibly, probably, or definitely drug related in greater than or equal to [0m[1;31m2[0m[31m% of patients treated with either alendronate or placebo are presented in the following table. ALENDRONATE: [0m
[31madverse_reactions: Table [0m[1;31m3[0m[31m Osteoporosis Studies in Men Adverse Reactions Considered Possibly, Probably, or Definitely Drug Related by the Investigators and Reported in Greater Than or Equal to [0m[1;31m2[0m[31m% of [0m
[31mPatients Two-Year Study One-Year Study Once Daily Alendronate Sodium Once Weekly Alendronate Sodium [0m[1;31m10[0m[31m mg % [0m[1;31m([0m[31mN = [0m[1;31m146[0m[1;31m)[0m[31m Placebo % [0m[1;31m([0m[31mN = [0m[1;31m95[0m[1;31m)[0m[31m [0m[1;31m70[0m[31m mg % [0m[1;31m([0m[31mN = [0m[1;31m109[0m[1;31m)[0m[31m Placebo % [0m[1;31m([0m[31mN = [0m[1;31m58[0m[1;31m)[0m[31m Gastrointestinal Acid [0m
[31mregurgitation [0m[1;31m4.1[0m[31m [0m[1;31m3.2[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m0.0[0m[31m Flatulence [0m[1;31m4.1[0m[31m [0m[1;31m1.1[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m0.0[0m[31m Gastroesophageal reflux disease [0m[1;31m0.7[0m[31m [0m[1;31m3.2[0m[31m [0m[1;31m2.8[0m[31m [0m[1;31m0.0[0m[31m Dyspepsia [0m[1;31m3.4[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m2.8[0m[31m [0m[1;31m1.7[0m[31m Diarrhea [0m[1;31m1.4[0m[31m [0m[1;31m1.1[0m[31m [0m[1;31m2.8[0m[31m [0m[1;31m0[0m[31m. ALENDRONATE: adverse_reactions: [0m[1;31m0[0m[31m Abdominal [0m
[31mpain [0m[1;31m2.1[0m[31m [0m[1;31m1.1[0m[31m [0m[1;31m0.9[0m[31m [0m[1;31m3.4[0m[31m Nausea [0m[1;31m2.1[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m6.2[0m[31m Post-Marketing Experience The following adverse reactions have been identified during post-approval use of alendronate sodium. Because these reactions [0m
[31mare reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Body as a Whole : [0m
[31mhypersensitivity reactions including urticaria and angioedema. Transient symptoms of myalgia, malaise, asthenia and fever have been reported with alendronate, typically in association with initiation [0m
[31mof treatment. Symptomatic hypocalcemia has occurred, generally in association with predisposing conditions. Peripheral edema. ALENDRONATE: adverse_reactions: Gastrointestinal : esophagitis, esophageal[0m
[31merosions, esophageal ulcers, esophageal stricture or perforation, and oropharyngeal ulceration. Gastric or duodenal ulcers, some severe and with complications have also been reported [0m[31m . Dental : [0m
[31mLocalized osteonecrosis of the jaw, generally associated with tooth extraction and/or local infection with delayed healing, has been reported [0m[31m . Musculoskeletal : bone, joint, and/or muscle pain, [0m
[31moccasionally severe and incapacitating [0m[31m ; joint swelling; low-energy femoral shaft and subtrochanteric fractures [0m[31m . Nervous system : dizziness and vertigo. ALENDRONATE: adverse_reactions: Pulmonary: [0m
[31macute asthma exacerbations Skin : rash [0m[1;31m([0m[31moccasionally with photosensitivity[0m[1;31m)[0m[31m, pruritus, alopecia, severe skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Special [0m
[31mSenses : uveitis, scleritis or episcleritis. Cholesteatoma of the external auditory canal [0m[1;31m([0m[31mfocal osteonecrosis[0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: ALENDRONATE has been reported to cause hypersensitivity reactions including urticaria and angioedema.[0m

[32mSOURCE: ALENDRONATE label[0m
[32mEXTRACT_START_END: Hypersensitivity reactions including urticaria and angioedema have been reported[0m[32m...[0m
*[1m([0morchestrator-angioedema-ALENDRONATE[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: ALENDRONATE has been reported to cause hypersensitivity reactions [0m
[34mincluding urticaria and angioedema.[0m

[34mSOURCE: ALENDRONATE label[0m
[34mEXTRACT_START_END: Hypersensitivity reactions including urticaria and angioedema have been reported[0m[34m...[0m
 [1m([0morchestrator-angioedema-ALENDRONATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-ALENDRONATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-angioedema-ALENDRONATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does ALENDRONATE increase or decrease the risk of angioedema?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether ALENDRONATE increases the risk of angioedema."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that ALENDRONATE has been reported to cause hypersensitivity reactions including urticaria and angioedema, citing the drug's label."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"ALENDRONATE increases the risk of angioedema."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-angioedema-ALENDRONATE[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-angioedema-ALENDRONATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-angioedema-ALENDRONATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-angioedema-ALENDRONATE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does ALENDRONATE increase or decrease the risk of angioedema?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether ALENDRONATE increases the risk of angioedema."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that ALENDRONATE has been reported to cause hypersensitivity reactions including urticaria and angioedema, citing the drug's label."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"ALENDRONATE increases the risk of angioedema."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does ALENDRONATE increase or decrease the risk of angioedema?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether ALENDRONATE increases the risk of angioedema.[0m
[1;31m2[0m[31m. FDAHandler responded that ALENDRONATE has been reported to cause hypersensitivity reactions including urticaria and angioedema, citing the drug's label.[0m
[31m        -----[0m
[31m        Final answer: ALENDRONATE increases the risk of angioedema.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-angioedema-ALENDRONATE[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-angioedema-ALENDRONATE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-angioedema-ALENDRONATE[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-angioedema-ALENDRONATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-angioedema-ALENDRONATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mALENDRONATE increases the risk of angioedema. This is based on the information provided by FDAHandler, which cited the ALENDRONATE label indicating that hypersensitivity reactions including urticaria [0m
[32mand angioedema have been reported.[0m
